Logo En IconLogo Mark IconIcelandic Intellectual Property Office

EP2535337

Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide sulfate and its amorphous form

  • Status:
    EP einkaleyfi: Þýðing ekki lögð inn
  • EP appl. date:
    18.7.2006
  • EP published:
    23.8.2017
  • EP application number:
    12160493.8
  • Max expiry date:
    17.7.2026
  • Title:
    Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide sulfate and its amorphous form

Timeline

Today
18.7.2006EP application
23.8.2017EP Publication

Owner

  • Name:
    Novartis AG
  • Address:
    Lichtstrasse 35, 4056, Basel, CH
  • Name:
    Novartis Pharma GmbH
  • Address:
    Brunner Strasse 59, 1230, Wien, AT

Inventor

  • Name:
    Manley, Paul W.
  • Address:
    Arlesheim, CH
  • Name:
    Shieh, Wen-Chung
  • Address:
    Berkeley Heights, NJ, US
  • Name:
    Sutton, Paul Allen
  • Address:
    Parsippany, NJ, US
  • Name:
    Karpinski, Piotr H.
  • Address:
    Lincoln Park, NJ, US
  • Name:
    Wu, Raeann
  • Address:
    Pine Brook, NJ, US
  • Name:
    Monnier, Stéphanie
  • Address:
    Raedersheim, FR
  • Name:
    Brozio, Jörg
  • Address:
    Basel, CH

Priority

  • Number:
    701405 P
  • Date:
    20.7.2005
  • Country:
    US
  • Number:
    716214 P
  • Date:
    12.9.2005
  • Country:
    US

Classification

  • Categories:
    C07D 401/14, A61K 31/506, A61P 35/00

Upload documents